[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR6613A - CHANGING THE EXPRESSION OF GENESIS WITH ADSss PRODUCED IN LIVE - Google Patents

CHANGING THE EXPRESSION OF GENESIS WITH ADSss PRODUCED IN LIVE

Info

Publication number
CR6613A
CR6613A CR6613A CR6613A CR6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A
Authority
CR
Costa Rica
Prior art keywords
expression
adsss
genesis
live
changing
Prior art date
Application number
CR6613A
Other languages
Spanish (es)
Inventor
A Conrad Charles
Chen Yin
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of CR6613A publication Critical patent/CR6613A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un metodo para alterar la expresion de una secuencia de acido nucleico objetivo en una celula objetivo mediante la produccion de ADNc de una sola cadena (ADNC-ss) en la celula objetivo in vivo.A method to alter the expression of a target nucleic acid sequence in a target cell by producing single-stranded cDNA (cDNA-ss) in the target cell in vivo.

CR6613A 1999-10-04 2002-04-03 CHANGING THE EXPRESSION OF GENESIS WITH ADSss PRODUCED IN LIVE CR6613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41156899A 1999-10-04 1999-10-04
US51470700A 2000-02-28 2000-02-28

Publications (1)

Publication Number Publication Date
CR6613A true CR6613A (en) 2004-04-21

Family

ID=27021437

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6613A CR6613A (en) 1999-10-04 2002-04-03 CHANGING THE EXPRESSION OF GENESIS WITH ADSss PRODUCED IN LIVE

Country Status (11)

Country Link
EP (1) EP1222259A1 (en)
JP (1) JP2003511025A (en)
KR (1) KR20020059608A (en)
CN (1) CN1276083C (en)
AU (1) AU7855300A (en)
BR (1) BR0014814A (en)
CA (1) CA2386246A1 (en)
CR (1) CR6613A (en)
IL (1) IL148946A0 (en)
MX (1) MXPA02003422A (en)
WO (1) WO2001025419A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
WO2002034951A2 (en) 2000-10-23 2002-05-02 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
CA2470033A1 (en) * 2001-12-14 2003-06-26 Yale University Intracellular generation of single-stranded dna
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
CA2582814A1 (en) * 2004-09-28 2006-04-06 Cytogenix, Inc. Single-stranded antimicrobial oligonucleotides and uses thereof
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102154269B (en) * 2011-01-06 2012-05-23 湖南农业大学 PCR-based rapid construction method of tandem repeat sequence, special primer pair and application
JP2019508037A (en) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ Compositions for enhancing targeted gene editing and methods of use thereof
CN108396043A (en) * 2017-02-06 2018-08-14 中国科学院上海应用物理研究所 A kind of preparation method and applications of the ends 5` phosphorylation single stranded DNA
EP3873537A4 (en) * 2018-11-02 2022-10-12 Nikegen Limited Recombinant parvoviral vectors and method of making and use thereof
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6298899A (en) * 1998-10-09 2000-05-01 Ingene, Inc. Production of ssdna (in vivo)
BR9914772A (en) * 1998-10-09 2001-12-11 Ingene Inc Set of genetic elements, vector, host cell, set for the production of a nucleic acid sequence, method for in vivo or in vitro production of a nucleic acid sequence, cdna transcription, inhibitor nucleic acid molecule, mrna transcription, heteroduplex molecule and pharmaceutical composition

Also Published As

Publication number Publication date
AU7855300A (en) 2001-05-10
KR20020059608A (en) 2002-07-13
CA2386246A1 (en) 2001-04-12
EP1222259A1 (en) 2002-07-17
IL148946A0 (en) 2002-09-12
BR0014814A (en) 2002-09-17
WO2001025419A1 (en) 2001-04-12
MXPA02003422A (en) 2004-09-10
JP2003511025A (en) 2003-03-25
CN1276083C (en) 2006-09-20
CN1399679A (en) 2003-02-26

Similar Documents

Publication Publication Date Title
ES2597953T3 (en) Oligoribonucleotide to inhibit the expression of a predetermined gene
AR031480A1 (en) 3-HYDROXIPROPIONIC ACID AND OTHER ORGANIC COMPOUNDS
CR6613A (en) CHANGING THE EXPRESSION OF GENESIS WITH ADSss PRODUCED IN LIVE
CY1106821T1 (en) METHOD FOR CULTIVATING CARTILAGE SUBSTITUTE AND BIOLOGICAL UTERUS PRODUCED ACCORDING TO THE METHOD
AR082240A2 (en) METHOD FOR OBTAINING PLANTS WITH MODIFIED GROWTH CHARACTERISTICS, A CONSTRUCTION; A CELL GUEST; A TRANSGENIC PLANT AND USES
AR024318A1 (en) NUCLEIC ACID MOLECULES OF WHEAT, CELLS OF TRANSGENIC PLANTS AND PLANTS AND THE USE OF THE SAME FOR THE MODIFIED ALMIDON PRODUCTION.
AR027600A1 (en) POLYPEPTIDES THAT HAVE ALFA-AMYLASE ALKALINE ACTIVITY AND THE NUCLEIC ACIDS THAT CODE IT
BR9612258B1 (en) interleukin-1beta converting enzyme inhibitors as well as pharmaceutical composition.
ES2175753T3 (en) BIOSYNTHETIC GRAFT AND METHOD FOR PRODUCTION.
NO20022359L (en) Inhibition of gene expression
ES2061720T3 (en) TRANSFORMATION OF PLANT TISSUE.
AR039716A1 (en) SEQUENCES OF NUCLEIC ACIDS RELATED TO THIOESTERASES AND METHODS OF USE FOR THE PRODUCTION OF PLANTS WITH MODIFIED FATTY ACIDS COMPOSITION
ES2059498T3 (en) PROCEDURE FOR THE PRODUCTION OF AVERMECTIN B AND CROPS FOR IT.
EP2816117A3 (en) Collagen producing plants and methods of generating and using same
DE60036537D1 (en) COMPOSITIONS FOR GENETHERAPY OF DIABETES
SV2005002082A (en) "PROLINA CCI-779, PRODUCTION AND USES OF THE SAME, AND ENZYMATIC SYNTHESIS OF TWO STAGES OF PROLINA CCI-779 AND CCI-779" REF. AM-101578SALVO
DE60213803D1 (en) Happier mapping
EE03955B1 (en) Use of nucleic acid for the manufacture of a medicament for transfecting at least some cells of the mammalian reproductive tract
DK0972445T3 (en) Chimeric mouse expressing a human antibody
DE60325611D1 (en) BENZOATE AND AN ANTILANEABLE PROMOTERS
CN204333588U (en) A kind of random fiber laser based on random phase shift fiber grating
BR0212227B1 (en) Fruit thinning agent and processes as well as their employment
ES2157690T3 (en) METHOD OF PRODUCING THE POWER LEVEL RECEIVED IN A BASE STATION OF A CDMA NETWORK AND BASE STATION FOR IMPLEMENTATION.
AR069074A1 (en) MODIFICATION OF LIGNIN BIOSYNTHESIS BY SUPPRESSION WITH NUCLEIC ACID SENSE
CR10319A (en) PRECISE FORMULATIONS DERIVED FROM NODULISPORIC ACID TO COMBAT PARASITES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)